| Project/Area Number |
13671255
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Teikyo University |
|---|
Principal Investigator |
OKINAGA Kota Teikyo University, School of Medicine Depertment of Surgery, Professor, 医学部, 教授 (00101098)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
IINUMA Hisae Teikyo University School of Medicine, Depertment of Surgery, Associate Professor, 医学部, 講師 (30147102)
|
|---|
| Project Period (FY) |
2001 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2003: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 2002: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 2001: ¥2,000,000 (Direct Cost: ¥2,000,000)
|
|---|
| Keywords | fusion cell / dendritic cell / Tumor vaccine / gastrointestinal cancer / CTL / 抗原提示能 / 癌ワクチン / 免疫療法 |
|---|
| Research Abstract |
(1)2001 : We examined the preventive and therapeutic effects of fusion cells prepared from spleen-derived endritic cells (DCs) transduced with the interleukin-2 (IL-2) gene and QRsP fibrosarcoma cells in a mouse lung metastasis model. Our results showed that immunization with fusion cells prepared from spleen-derived DCs and tumor cells is capable of inducing preventive and therapeutic anti-tumor immunity against lung metastasis, and codification by the IL-2 gene may increase anti-tumor efficacy.
(2)2002 : We examined the effects of two BRMs OK432 and PSK for the functional maturation of DCs, and compared with that of lipopolysaccharide (LPS) and a maturation cocktail (IL-1 β,TNF-α, IL-6 and PGE2). Our results showed that OK432 is a GMP-grade reagent that promotes functional maturation of DCs.
(3)2003 : We studied phase I clinical trial of DC fusion vaccine in patients with gastrointestinal cancer. Nine patients with advanced or recurrent gastrointestinal cancer that was unresponsive to standard surgical therapy and chemotherapy were enrolled in this study after informed consent was obtained. Fusion of irradiated tumor cells and DCs was created by polyethylene glycol and electroporation. The fusion vaccine was injected subcutaneously into the inguinal region four times every two weeks. There were no adverse effects or autoimmune responses after vaccination in any patient. The clinical response was stable in five patients, and disease progression in four patients.
|
